Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells
about
Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic PathwaysInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineT-Cell Therapy: Options for Infectious DiseasesDirect tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.Active Immunotherapy of Cancer.Vaccines targeting helper T cells for cancer immunotherapy.Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer.Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.CD74 and intratumoral immune response in breast cancer.Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
P2860
Q26781304-53F89659-B883-4181-95D0-DFD6D60A5F7DQ26782583-9C2660AB-732E-4DB8-A014-4BA8F2E98989Q26786661-0DE1D469-7774-4715-9841-05C34AFE8B8CQ30667174-131A7BFA-91AD-4E95-85F6-22ADECB92DCDQ35898801-30134D7D-2700-4805-80BD-9B88C8E2594DQ35996647-1E23BA83-379F-4A33-AB81-C4D97C8F6D34Q36382255-0E95A64C-4650-4D60-88D4-71C1DE957831Q38635419-89124C15-0671-4EAF-BB33-EA1B6984154BQ38649958-3C5C025E-6396-45B5-8571-7429FD9EF381Q38668305-440DA04D-2A21-4834-A964-5718F46D6039Q38754328-1298816C-6905-4571-B14A-B59463A1D9A3Q38935082-1B611552-E39A-45E5-987E-FBCDED27E2EFQ39084138-A995ABE8-D772-47D8-8B22-7AD3618261FAQ40329387-1BDF9FB0-1EFB-4734-B24B-69689612D501Q40448718-3BB3BB0D-A148-4D31-A07E-7D94A391F82BQ41808474-70B37ECF-B19F-42FA-8A3E-13D659987CF1Q42695310-641EE809-85C7-4E3F-AE28-542DC293A445
P2860
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Nonclassical antigen-processin ...... ition by NY-ESO-1-specific CD4
@nl
Nonclassical antigen-processin ...... -ESO-1-specific CD4(+) T cells
@en
type
label
Nonclassical antigen-processin ...... ition by NY-ESO-1-specific CD4
@nl
Nonclassical antigen-processin ...... -ESO-1-specific CD4(+) T cells
@en
prefLabel
Nonclassical antigen-processin ...... ition by NY-ESO-1-specific CD4
@nl
Nonclassical antigen-processin ...... -ESO-1-specific CD4(+) T cells
@en
P2093
P2860
P1476
Nonclassical antigen-processin ...... -ESO-1-specific CD4(+) T cells
@en
P2093
Immanuel Luescher
Junko Matsuzaki
Lloyd J Old
Protul Shrikant
Sacha Gnjatic
Takemasa Tsuji
P2860
P304
P356
10.1158/2326-6066.CIR-13-0138
P50
P577
2013-12-17T00:00:00Z